Conv. Plasma
Nigella Sativa
Peg.. Lambda

All ibuprofen studies
Meta analysis
Home COVID-19 treatment researchIbuprofenIbuprofen (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression -240% Improvement Relative Risk Ibuprofen for COVID-19  Choi et al.  Prophylaxis Is prophylaxis with ibuprofen beneficial for COVID-19? PSM retrospective 72 patients in South Korea (Mar - Mar 2020) Higher progression with ibuprofen (not stat. sig., p=0.26) Choi et al., J. Clinical Medicine, Jun 2020 Favors ibuprofen Favors control

Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea

Choi et al., Journal of Clinical Medicine, doi:10.3390/jcm9061959
Jun 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 293 patients in South Korea, showing higher risk of progression with ibuprofen use, without statistical significance.
This study includes metformin and ibuprofen.
risk of progression, 240.0% higher, OR 3.40, p = 0.26, treatment 6 of 36 (16.7%) cases, 2 of 36 (5.6%) controls, case control OR, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Choi et al., 23 Jun 2020, retrospective, South Korea, peer-reviewed, median age 29.0, 8 authors, study period 5 March, 2020 - 18 March, 2020.
Contact: (corresponding author),,,,,,,
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIbuprofenAll
Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea
Min Hyuk Choi, Hyunmin Ahn, Han Seok Ryu, Byung-Jun Kim, Joonyong Jang, Moonki Jung, Jinuoung Kim, Seok Hoon Jeong
Journal of Clinical Medicine, doi:10.3390/jcm9061959
A rapid increase in the number of patients with coronavirus disease 19 (COVID-19) may overwhelm the available medical resources. We aimed to evaluate risk factors for disease severity in the early stages of COVID-19. The cohort comprised 293 patients with COVID-19 from 5 March 2020, to 18 March 2020. The Korea Centers for Disease Control and Prevention (KCDC) classification system was used to triage patients. The clinical course was summarized, including the impact of drugs (angiotensin II receptor blockers [ARB], ibuprofen, and dipeptidyl peptidase-4 inhibitors [DPP4i]) and the therapeutic effect of lopinavir/ritonavir. After adjusting for confounding variables, prior history of drug use, including ARB, ibuprofen, and DPP4i was not a risk factor associated with disease progression. Patients treated with lopinavir/ritonavir had significantly shorter progression-free survival than those not receiving lopinavir/ritonavir. KCDC classification I clearly distinguished the improvement/stabilization group from the progression group of COVID-19 patients (AUC 0.817; 95% CI, 0.740-0.895).
Author Contributions: Conceptualization, M.H.C., H.A., and S.H.J.; data curation, M.H.C. and H.A.; writingoriginal draft, M.H.C.; writing-review and editing, H.S.R., B.-J.K., J.J., M.J., and J.K. All authors have read and agreed to the published version of the manuscript. Conflicts of Interest: The authors declare no conflicts of interest. Appendix A
Brindley, Gold, Shnider, Oviedo, Gorman et al., Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide, J. Chronic Dis
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2001282
Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, J. Chronic Dis, doi:10.1016/0021-9681(87)90171-8
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study, Lancet, doi:10.1016/S0140-6736(20)30211-7
Deng, Peng, Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China, J. Clin. Med, doi:10.3390/jcm9020575
Ferrario, Jessup, Chappell, Averill, Brosnihan et al., Effect of angiotensin-converting enzyme inhibition and angiotensin ii receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation, doi:10.1161/CIRCULATIONAHA.104.510461
Fine, Auble, Yealy, Hanusa, Weissfeld et al., A prediction rule to identify low-risk patients with community-acquired pneumonia, N. Engl. J. Med, doi:10.1056/NEJM199701233360402
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med, doi:10.1056/NEJMoa2002032
Guo, Wei, Zhang, Wu, Li et al., Clinical features predicting mortality risk in patients with viral pneumonia: The mulbsta score, Front. Microbiol, doi:10.3389/fmicb.2019.02752
Gurwitz, Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics, Drug Dev. Res, doi:10.1002/ddr.21656
Hill, Discussion of research using propensity-score matching: Comments on "A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003" by peter austin, statistics in medicine, Stat. Med, doi:10.1002/sim.3245
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Hui, Azhar, Madani, Ntoumi, Kock et al., The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.01.009
Kim, Choe, Oh, Oh, Kim et al., The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: Implication for infection prevention and control measures, J. Korean Med. Sci, doi:10.3346/jkms.2020.35.e61
Li, Huang, Wang, Wang, Liang et al., COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis, J. Med. Virol, doi:10.1002/jmv.25757
Li, Wu, Wu, Guo, Chen et al., The clinical and chest CT features associated with severe and critical COVID-19 pneumonia, Investig. Radiol, doi:10.1097/RLI.0000000000000672
Lim, Van Der Eerden, Laing, Boersma, Karalus et al., Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study, Thorax, doi:10.1136/thorax.58.5.377
Lu, Stratton, Tang, Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle, J. Med. Virol, doi:10.1002/jmv.25678
Mcmichael, Currie, Clark, Pogosjans, Kay et al., Epidemiology of COVID-19 in a long-term care facility in king county, Washington. N. Engl. J. Med, doi:10.1056/NEJMoa2005412
Peng, Meng, Guan, Leng, Zhu et al., Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV, Zhonghua Xin Xue Guan Bing Za Zhi
Qiao, Wang, Chen, Zhang, Liu et al., Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats, Cardiology, doi:10.1159/000375362
Richman, Whitley, Hayden, Clinical Virology
Shi, Yu, Zhao, Wang, Zhao et al., Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan, Crit. Care, doi:10.1186/s13054-020-2833-7
Tian, Hu, Lou, Chen, Kang et al., Characteristics of COVID-19 infection in Beijing, J. Infect, doi:10.1016/j.jinf.2020.02.018
Vaduganathan, Vardeny, Michel, Mcmurray, Pfeffer et al., Renin-angiotensinaldosterone system inhibitors in patients with COVID-19, N. Engl. J. Med, doi:10.1056/NEJMsr2005760
Vankadari, Wilce, Emerging Wuhan (COVID-19) coronavirus: Glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26, Emerg. Microbes Infect, doi:10.1080/22221751.2020.1739565
Verdecchia, Angeli, Mazzotta, Ambrosio, Reboldi, Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: Should they be used together?, Curr. Vasc. Pharmacol, doi:10.2174/157016110793563924
Vuille-Dit-Bille, Camargo, Emmenegger, Sasse, Kummer et al., Human intestine luminal ace2 and amino acid transporter expression increased by ace-inhibitors, Amino Acids, doi:10.1007/s00726-014-1889-6
Wan, Shang, Graham, Baric, Li, Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus, J. Virol, doi:10.1128/JVI.00127-20
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Wyss, Girman, Locasale, Brookhart, Sturmer, Variable selection for propensity score models when estimating treatment effects on multiple outcomes: A simulation study, Pharmacoepidemiol. Drug Saf, doi:10.1002/pds.3356
Xiong, Sun, Liu, Fan, Zhao et al., Clinical and high-resolution CT features of the COVID-19 infection: Comparison of the initial and follow-up changes, Investig. Radiol, doi:10.1097/RLI.0000000000000674
Xu, Chen, Wang, Feng, Zhou et al., Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission, Sci. China Life Sci, doi:10.1007/s11427-020-1637-5
Young, Ong, Kalimuddin, Low, Tan et al., Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore, JAMA, doi:10.1001/jama.2020.3204
Zhang, Dong, Cao, Yuan, Yang et al., Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy, doi:10.1111/all.14238
Zhao, Zhong, Xie, Yu, Liu, Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: A multicenter study, AJR Am. J. Roentgenol, doi:10.2214/AJR.20.22976
Zubrod, Schneiderman, Frei, Iii, None
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop